Leobardo Sauque-Reyna

Learn More
OBJECTIVE When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin (HbA1c) remains elevated because of postprandial hyperglycemia, the next therapeutic step is controversial. We examined the efficacy and safety of lixisenatide in patients with HbA1c still elevated after(More)
RESEARCH DESIGN AND METHODSdThis double-blind, parallel-group trial enrolled patients with HbA1c 7–10% despite oral therapy. Insulin glargine was added and systematically titrated during a 12-week run-in, after which candidates with fasting glucose#7.8 mmol/L and HbA1c 7–9% were randomized to lixisenatide 20 mg or placebo for 24 weeks while insulin(More)
AIMS Socioeconomic changes in Latin American countries have led to an increased prevalence of type 2 diabetes (T2D). We examined the effects of exenatide twice daily (BID) or insulin lispro, each added to insulin glargine, in Latin American patients with T2D. METHODS This was a subgroup analysis of patients from Argentina and Mexico in the 4B study(More)
  • 1